Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

4.970 +0.070 (+1.43%)
Streaming Delayed Price Updated: 1:48 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 314,056
Open 4.970
Bid (Size) 4.970 (4)
Ask (Size) 4.980 (1)
Prev. Close 4.900
Today's Range 4.705 - 4.970
52wk Range 1.575 - 7.270
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+27.1%
+27.1%
1 Month
-0.8%
-0.8%
3 Month
+65.7%
+65.7%
6 Month
-12.2%
-12.2%
1 Year
+190.6%
+190.6%

More News

Read More
Earnings Scheduled For May 8, 2025
Via Benzinga
Exploring Amylyx Pharma's Earnings Expectations
Via Benzinga
4 Analysts Assess Amylyx Pharma: What You Need To Know
Via Benzinga
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 4, 2025
Via Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 4.970
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 05/30/25 01:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.